Interleukin-based therapy for Age-associated dementia and Alzheimer’s disease (AD): IL-6 increases the expression of AGE receptor 1 (AGER1), the longevity-promoting gene Sirtuin-1 and decreases advanced glycation end products (AGEs) via down regulation of its target gene, 12/June/2015, 8.43 pm

Natural product-based anti-viral therapy: SOCS1(Suppressor of cytokine signaling 1) suppresses porcine reproductive and respiratory syndrome virus infection via up regulation of its target gene, 12/June/2015, 10.29 pm
June 12, 2015
Rescuing the cerebral ischemia-mediated brain damage: MiRNA-107 attenuates cerebral ischemia-mediated brain damage via down regulation of its target gene, 12/June/2015, 9.48 pm
June 12, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, Interleukinbased therapy for Age-associated dementia and Alzheimer’s disease (AD): IL-6 increases the expression of AGE receptor 1 (AGER1), the longevity-promoting gene Sirtuin-1 and decreases advanced glycation end products (AGEs) via down regulation of its target gene, 12/June/2015, 8.43 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance:  This study suggests, for the first time, that IL-6, by decreasing the expression of its target gene, it may: (1) increase the expression of AGE receptor 1 (AGER1); (2) increase the expression of longevity-promoting gene Sirtuin-1; and (3) decrease advanced glycation end products (AGEs). Thus, pharmacological formulations encompassing “IL-6 activators”  can be used to decrease ageing and increase the life-span of an individual.

Undisclosed information: How IL-6 increases the expression of AGER1 

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Comments are closed.